Health inequalities modular update to NICE health technology evaluations: the manual (PMG36) Methods / process manual consultation NICE process and methods 31 January 2025 Highly specialised ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Tebentafusp (Kimmtrak, Immunocore) is indicated 'as monotherapy for the treatment of human leukocyte antigen (HLA)‑A*02:01-positive adult patients with unresectable or metastatic uveal melanoma'. The ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. The minutes of each evaluation committee meeting, which include the names of ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Document (FAD) on tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma ...

has the HLA‑A*02:01 genotype and is unresectable (cannot be surgically removed) or metastatic (has spread to other parts of the body). Your healthcare professionals should give you clear information, ...

NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 5 sources on ...